Joseph Edelman, of Perceptive Advisors and a director at Cerevel Therapeutics Holding (NASDAQ:CERE), made a large insider buy on August 26, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Edelman purchased 68,047 shares of Cerevel Therapeutics at a price of $30.23 per share. The total transaction amounted to $2,057,061.
Following the transaction, Edelman now owns 5,086,727 shares of the company, worth $161,045,777 as of Tuesday’s close. Cerevel Therapeutics shares closed up 2.23% on Tuesday at $31.66.
Why Insider Transactions Are Important
Insider transactions shouldn’t be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an “insider” refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Transaction Codes To Focus On
Investors prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
To get more information on previous transactions, check out the insider’s net worth page here.
To learn more about investing, see other tools here.